Correction to: Scientific Reports 10.1038/s41598-025-32428-6, published online 21 December 2025
The original version of the Article contained errors in Figure 1, 2, 4 and 6. Figure 1 was published as Figure 6.
The original Fig. 1 and the accompanying legend appear below.
Fig. 1.
Body weight gain trajectories and verification of gene transduction in rats injected with viral vectors expressing GFP or BDNFmyc within the paraventricular nucleus of hypothalamus (PVN). A: Diagram indicating the location of bilateral viral vector injections into the PVN. B: Representative fluorescent images of coronal brain sections ~ 1.8 mm posterior to bregma showing bilateral PVN expression of GFP and unilateral or bilateral PVN expressions of BDNFmyc. 3 V: third ventricle. C: Body weight change of rats involved in immunohistochemical vector verifications. Weight changes from day 0 are expressed as mean ± SEM. Rats with confirmed bilateral PVN expression of BDNFmyc (n = 6) showed a markedly reduced weight gain compared to PVN-GFP controls (n = 6) over the duration of the study. Body weight trajectories from rats with unilateral PVN expression of BDNFmyc (n = 2) are colored in magenta and are not included in the overall PVN-BDNF mean. D: Violin plots show distribution of body weight changes for all PVN-GFP (n = 38) and PVN-BDNF animals (n = 30) included in the study as well as PVN-BDNF rats excluded (n = 10) due to missed injections. The horizontal dotted line shows our body weight change cutoff criteria (127.3 g) used to determine if animals were likely to have bilaterial or unilateral PVN-BDNF injections.
Figure 2 was omitted from the original version of the Article.
The original Fig. 2 and the accompanying legend appear below.
Fig. 2.
Assessment of BDNF-induced cardiovascular changes and activation of neuroendocrine stress pathways 14 to 19 weeks post viral vector injections. A: Cardiac left ventricle weight (LV) to body weight (BW) ratio (left, n = 4/group). B: Representative radiotelemetric recordings of mean arterial pressure (MAP) and heart rate (HR) averaged over 5 days in a single PVN-BDNF and a single PVN-GFP rat at 14 weeks after vector injections; shaded rectangle indicates nighttime (Lights OFF). C-D: Plasma corticosterone (GFP: n = 8; BDNF: n = 5) and AVP (GFP: n = 4; BDNF: n = 6) levels measured from blood samples collected from isoflurane-anesthetized rats using cardiac punctures before euthanasia. Results are expressed as mean ± SEM. Statistical significance was tested with unpaired t-test.
Figure 4 was a duplication of Figure 3.
The original Fig. 4 and the accompanying legend appear below.
Fig. 4.
Average water consumption, urine production, and urine osmolality at weeks 3, 6, 10, and 14 following vector injections. A: Average daily water consumption observed at all timepoints averaged over the 48-h sessions in PVN-GFP and PVN-BDNF rats. B: Daily urine production at all timepoints averaged over the 48-h sessions in PVN-GFP and PVN-BDNF rats. C: Urine osmolality at all timepoints assessed in urine collected at the conclusion of the 48-h recording sessions in PVN-GFP and PVN-BDNF rats. Results are expressed as mean ± SEM. A Two-way repeated measures ANOVA with Tukey’s post hoc test was used. *p < 0.05, **p < 0.01 vs. control (GFP: n = 8; BDNF: n = 6).
Finally, the original Figure 6 was published as Figure 2..
The original Fig. 6 and the accompanying legend appear below.
Fig. 6.
Bladder capacity and volume-pressure curves in ex vivo pressurized bladders from PVN-GFP and PVN-BDNF rats at weeks 17 to 19 after vector injections. A: Bladder capacity, defined as the volume a urinary bladder holds once the pressure reaches 25 mmHg. B: Bladder pressure vs. infused volume. C: Bladder pressure vs. infused volume expressed as % of bladder capacity). Unpaired t-test was used for bladder capacity and two-way repeated measures ANOVA with Tukey’s post hoc test was used for volume-pressure curves (GFP: n = 8; BDNF: n = 6). Results are expressed as mean ± SEM. P values are shown above data sets.
The original Article has been corrected.